Smart radiation: daily adjustments may spare prostate cancer patients from side effects

NCT ID NCT07276438

Recruiting now Symptom relief Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether using daily MRI or CT scans to adjust radiation plans in real time can lower side effects for men with localized prostate cancer. 186 participants will receive standard stereotactic body radiation therapy (SBRT) either with or without daily plan adaptation. The main goal is to see if fewer men experience urinary problems within 90 days of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiation therapy (SBRT) with daily image-guided adaptation
What this could lead to: If successful, this approach could reduce urinary and bowel side effects from radiation therapy for prostate cancer, making treatment safer and more comfortable.
What could go wrong: This is an early-stage trial focused on side effects, not cure rates. The daily adaptation process is complex and may not significantly improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALIZED PROSTATE ADENOCARCINOMA STAGE I PROSTATE CANCER AJCC V8 STAGE II PROSTATE CANCER AJCC V8 STAGE III PROSTATE CANCER AJCC V8

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.